DCPXF (DanCann Pharma AS) EPS without NRI: $-0.40 (TTM As of Sep. 2025)


DCPXF DanCann Pharma AS DCPXF
20 GF Score
Price $10.00
GF Value $37.14
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS EPS without NRI?

DanCann Pharma AS DCPXF 20 EPS without NRI is $-0.40 as of Sep. 2025. GuruFocus rates DCPXF with a GF Score™ of 20/100 and a GF Value™ of $37.14. The stock has 3 warning signs investors should review.

DanCann Pharma AS's earnings per share without non-recurring items for the three months ended in Sep. 2025 was $-0.06. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.40.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 73.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for DanCann Pharma AS's EPS without NRI or its related term are showing as below:

DCPXF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -127.1   Med: -56.8   Max: 73.8
Current: 73.8

During the past 7 years, DanCann Pharma AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 73.80% per year. The lowest was -127.10% per year. And the median was -56.80% per year.

DCPXF's 3-Year EPS without NRI Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 9.6 vs DCPXF: 73.80

DanCann Pharma AS's EPS (Diluted) for the three months ended in Sep. 2025 was $-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.40.

DanCann Pharma AS's EPS (Basic) for the three months ended in Sep. 2025 was $-0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.40.


DanCann Pharma AS  (GREY:DCPXF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


DanCann Pharma AS EPS without NRI Related Terms


DanCann Pharma AS EPS without NRI Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS EPS without NRI Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial -8.43 -16.89 -10.10 -29.05 -0.28

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.14 -0.09 -0.11 -0.06

DCPXF vs ZTS, UTHR, RGC: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DanCann Pharma AS PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where DanCann Pharma AS's PE Ratio without NRI falls into.


DCPXF
20GF Score
DanCann Pharma AS DCPXF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.40 mean?
DanCann Pharma AS (DCPXF) has a EPS without NRI of $-0.40 as of Sep. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's EPS without NRI too high?
DanCann Pharma AS's current EPS without NRI is $-0.40. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's EPS without NRI compare to ZTS and UTHR?
DanCann Pharma AS's EPS without NRI of $-0.40 can be compared against companies in the Drug Manufacturers industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on DanCann Pharma AS and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current EPS without NRI is $-0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current EPS without NRI of $-0.40. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current EPS without NRI is $-0.40. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current EPS without NRI is $-0.40 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DanCann Pharma AS (DCPXF) Overvalued in 2026?

Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued. The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.

Key valuation signals for DCPXF:

  • EPS without NRI: $-0.40
  • GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score

Get the complete analysis for DCPXF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$37.14
GF Value